A. Allred

发表

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

K. Flaherty, J. Sosman, I. Puzanov, 2012, The New England journal of medicine.

Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors.

D. Smith, D. Barker, D. Olmos, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

R. Salgia, Melissa L. Johnson, R. Knoblauch, 2020, JTO clinical and research reports.

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

T. Yap, D. Barker, Rohini Sharma, 2011, Clinical Cancer Research.

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

K. Flaherty, G. Shapiro, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Contribution of Angiotensin-(1–7) to Blood Pressure Regulation in Salt-Depleted Hypertensive Rats

A. Allred, K. Yamada, D. Averill, 2000, Hypertension.

Pathways of angiotensin-(1-7) metabolism in the kidney.

A. Allred, C. Ferrario, M. Chappell, 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

R. Bernards, C. Atreya, J. Schellens, 2014 .

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

S. Jagannath, A. Jakubowiak, N. Munshi, 2021, The Lancet.

Pathways for angiotensin-(1---7) metabolism in pulmonary and renal tissues.

D. Diz, A. Allred, C. Ferrario, 2000, American journal of physiology. Renal physiology.

A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.

R. Motzer, M. Voss, B. Rini, 2014 .

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

S. Jagannath, A. Jakubowiak, N. Munshi, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.

R. Salgia, Melissa L. Johnson, V. Papadimitrakopoulou, 2019, Journal of Clinical Oncology.

BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).

R. Kurzrock, D. Ryan, A. Venook, 2012 .

Targeted Proteomic Profiling of Renal Na+ Transporter and Channel Abundances in Angiotensin II Type 1a Receptor Knockout Mice

M. Knepper, H. Brooks, T. Coffman, 2002, Hypertension.

Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2015, Clinical pharmacology in drug development.

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

A. Tolcher, N. Ibrahim, K. Papadopoulos, 2014, Cancer Chemotherapy and Pharmacology.

Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.

E. Lee, B. Peng, A. Allred, 2011, British journal of clinical pharmacology.

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2021, Blood.

Differential actions of renal ischemic injury on the intrarenal angiotensin system.

D. Diz, A. Allred, C. Ferrario, 2000, American journal of physiology. Renal physiology.

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

S. Jagannath, A. Jakubowiak, J. Goldberg, 2019, Blood.

Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, J. Goldberg, 2020 .

Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice.

M. Donoghue, N. Philip, H. Rockman, 2006, The Journal of clinical investigation.

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

S. Jagannath, A. Jakubowiak, J. Goldberg, 2019, Blood.

Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, P. Hari, 2020, Transplantation and Cellular Therapy.

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2020 .

S. Jagannath, A. Jakubowiak, P. Hari, 2020, Transplantation and Cellular Therapy.

Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis

S. Jagannath, A. Jakubowiak, P. Hari, 2021, Blood.

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

S. Jagannath, A. Jakubowiak, P. Hari, 2021 .